SGTX Sigilon Therapeutics, Inc.

Sigilon is a clinical-stage biotechnology company pioneering a new class of therapeutics and seeking to develop functional cures for patients with chronic diseases.

As of 09/30/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/03/2020
Outstanding shares:  32,399,257
Average volume:  42,627
Market cap:   $15,551,643
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BLGZBP7
Valuation   (See tab for details)
PE ratio:   -0.23
PB ratio:   0.25
PS ratio:   3.02
Return on equity:   -111.78%
Net income %:   -1,400.52%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy